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Psoriasis is a complex inflammatory disease mediated by tumor necrosis factor (TNF)-a and cytokines secreted
by specialized T-cell populations, e.g., IL-17, IL-22, and IFN-g. The mechanisms by which innate and adaptive
immune cytokines regulate inflammation in psoriasis are not completely understood. We sought to investigate
the effects of TNF-a and IL-17 on keratinocyte (KC) gene profile, to identify genes that might be coregulated by
these cytokines and determine how synergistically activated genes relate to the psoriasis transcriptome. Primary
KCs were stimulated with IL-17 or TNF-a alone, or in combination. KC responses were assessed by gene array
analysis, followed by reverse transcriptase-PCR confirmation for significant genes. We identified 160 genes that
were synergistically upregulated by IL-17 and TNF-a, and 196 genes in which the two cytokines had at least an
additive effect. Synergistically upregulated genes included some of the highest expressed genes in psoriatic
skin with an impressive correlation between IL-17/TNF-a-induced genes and the psoriasis gene signature. KCs
may be key drivers of pathogenic inflammation in psoriasis through integrating responses to TNF-a and IL-17.
Our data predict that psoriasis therapy with either TNF or IL-17 antagonists will produce greater modulation of
the synergistic/additive gene set, which consists of the most highly expressed genes in psoriasis skin lesions.
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INTRODUCTION
Psoriasis is a chronic skin disease characterized by extensive
inflammation and altered keratinocyte (KC) differentiation
(Krueger and Bowcock, 2005). The dermal infiltrate is a
mixture of cells (Lowes et al., 2007) that secrete many
proinflammatory mediators, ultimately creating pathogenic
inflammation. Although cellular and molecular alterations in
psoriatic lesions are extremely complex, with more than
2000 genes with altered expression (Zhou et al., 2003), we
are seeking to define how key cytokines of innate or adaptive
immunity may interact to create the typical inflammatory
pathways of psoriasis vulgaris skin lesions.
One leukocyte subset of extreme interest in psoriasis is the
Th17 T-cell subset, with ability to produce IL-17 and IL-22.
These cells were shown (in vitro) to differentiate from naive
CD4þ T cells after IL-6 and TGF-b stimulation, with IL-23 as
the major survival factor (Morishima et al., 2009). This T-cell
subset and the expression levels of IL-23, IL-17, and IL-22 are
highly upregulated in psoriatic skin (Lee et al., 2004; Zaba
et al., 2007). Recently, IL-17-producing CD8þ T cells (Tc17)
were found to be significantly increased within the psoriatic
epidermis (Ortega et al., 2009), suggesting that both Th17/
Tc17 subsets contribute to increased IL-17 expression in
psoriatic lesions, supporting the role of IL-17 as the most
important effector cytokine in psoriasis pathogenesis (Lowes
et al., 2008; Ortega et al., 2009). IL-17 receptor antagonism
was recently shown to completely reverse the psoriatic
phenotype (Russell et al., 2010). This is surprising given that
IL-17 regulates only a small list of 35–40 genes in human KCs
(Nograles et al., 2008) and human epidermal KCs are the
dominant skin cell population expressing the IL-17 receptor,
which exerts potent proinflammatory effects (Albanesi et al.,
1999; Liang et al., 2006; Wilson et al., 2007; Harper et al.,
2009).
Tumor necrosis factor (TNF)-a is another potent inflam-
matory cytokine that is highly expressed in psoriatic skin. This
cytokine has a crucial role in psoriasis pathogenesis, as
demonstrated by the efficacy of TNF-a-targeted therapeutics.
TNF-a is a powerful inducer of inflammatory gene products
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in human KCs, some of which overlap with IL-17-regulated
genes in KCs (Zaba et al., 2007). TNF-a regulates the
transcription of target genes mainly through activation of
NF-kB, and TNF-a-induced genes in KCs are largely
consistent with known NF-kB target genes. Similarly, IL-17
signals in part through the NF-kB pathway, although its major
signaling pathway is through CCAAT/enhancer binding
proteins (C/EBP) transcription factors. Several IL-17 finger-
print genes (e.g., CXCL1, MIP-2, CXCL5, IL-6, LCN2, and
COX2) are transcribed by C/EBP-b and C/EBP-d (Ruddy et al.,
2004b; Shen et al., 2005, 2006).
As either TNF or IL-17 blockade can potentially reverse
psoriasis disease (Zaba et al., 2007; Russell et al., 2010), we
hypothesized that perhaps unappreciated interactions of TNF
and IL-17 regulate gene circuits in KCs as well as in psoriatic
lesions. Synergistic activation of some genes by IL-17 and TNF-a
has been previously observed in osteoblasts, fibroblasts, and
bone marrow stromal cells (Ruddy et al., 2004b; Shen et al.,
2005, 2006), possibly reflecting the regulation of common
genes by multiple transcription factors. Two previous studies,
focusing on a limited number of genes, reported IL-8 (Albanesi
et al., 1999) and CCL20 (Homey et al., 2000) to be
synergistically upregulated by this cytokine combination in
human KCs. A recent study, which used a five-cytokine
mixture (including IL-17A, IL-22, oncostatin M, IL-1a, and
TNF-a), examined a limited set of preselected genes by
complementary DNA microarray analysis. They detected
synergistic induction for 14 genes, with additive effects for 6
genes in KCs (Guilloteau et al., 2010). Although IL-17 and
TNF-a are clearly an important part of the report, the synergism
was demonstrated for a complex five-cytokine interaction,
without direct proof of a TNF/IL-17 synergy. Hence, we
conducted a more comprehensive analysis of KC responses to
IL-17, TNF-a, and the combination of both cytokines using
gene arrays. Our work increases the number of genes
coregulated by IL-17 and TNF-a to more than 350, with either
additive (196) or synergistic (160) effects. Our data predict that
in vivo treatment of psoriasis with either TNF or IL-17
antagonists will produce greater modulation of the synergis-
tic/additive gene sets, as the dual-regulated genes are among
the most highly expressed in psoriasis vulgaris skin lesions.
RESULTS
Previous experiments have shown that KC responses to IL-17
or TNF-a are dose dependent. To define cytokine-regulated
gene sets and determine the ‘‘near maximal’’ modulation of
gene expression, several previous genomic profiling experi-
ments were conducted using relatively high concentrations of
these cytokines (Banno et al., 2004). Seeking to define KC
responses to IL-17, TNF-a, or a combination of these
cytokines, we used IL-17 at 200 ngml1, as previously
described (Nograles et al., 2008; Harper et al., 2009). As
responses to TNF-a show a relatively steep dose–response
relationship (Harper et al., 2009), we examined the modula-
tion of two model inflammatory genes (IL-8 and S100A7) after
treatment with 0.1, 1, and 10 ngml1 of TNF-a and IL-17/
TNF-a combination across this range of TNF-a concentrations
(Figure 1). As expected, IL-17 and TNF-a individually
induced KC expression of IL-8. The combination of IL-17
with different concentrations of TNF-a strongly induced the
expression of IL-8 mRNA at higher levels than the additive
values of the individual cytokines, implying synergistic
induction of the target gene. We observed the same
phenomenon for S100A7, wherein modest gene induction
was observed after individual treatment with IL-17 and
TNF-a, but the combination of IL17/TNF-a was synergistic
for S100A7 mRNA increases across all TNF-a concentrations.
We further explored whether a broader set of inflamma-
tion- or differentiation-related genes in KCs could be
regulated by IL-17/TNF-a combination. To answer this
question, we treated independently derived (n¼3) primary
KC cultures with individual or a combination of cytokines
and evaluated their mRNA levels on whole-genome arrays.
Because of the many variables tested and considerably lower
cost per array, we used Illumina arrays (Illumina, San Diego,
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Figure 1. Keratinocyte responses to IL-17, tumor necrosis factor (TNF)-a, or
a combination of these cytokines as examined by modulation of two model
inflammatory genes, IL-8 and S100A7. The combination of 200 ngml1 of
IL-17 with different TNF-a concentrations (0.1, 1, or 10 ngml1) showed
synergistic induction of both IL-8 and IL-17 mRNA expression, at much higher
levels than the additive values of the individual cytokines.
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CA), although most single-cytokine profiling experiments
have been previously carried out on an Affymetrix platform
(Central Expressway, Santa Clara, CA). However, as Illumina
and Affymetrix arrays are different, we needed to first
redefine KC responses to individual cytokines on an Illumina
platform.
Identification of induced genes by IL-17 in human KC
Using an Illumina platform, we identified 47 upregulated
probes (42 unique genes as defined by ENTREZ identifiers)
and 4 downregulated probes (4 genes) by IL-17, with a fold
change (FCH) 41.3 and a false discovery rate o0.3
(Supplementary Table S1 online). IL-17 induced high mRNA
expression levels of (i) the IL-1 family of cytokines, i.e., IL-1F9
and IL-1B; (ii) chemoattractants, i.e., IL-8, CCL20, CXCL1,
and CXCL2; and (iii) innate immune mediators, i.e., DEFB4,
LCN2, S100A8, and S100A9.
We then compared this IL-17 signature with genes
previously identified using Affymetrix arrays (Nograles et al.,
2008; Figure 2a). In all, 12 of the 42 upregulated genes in this
study are not represented in AffymetrixU133A2, representing
IL-17 response genes that, to our knowledge, are previously
unreported. Of the 30 genes represented on both platforms and
upregulated on Illumina arrays (Figure 2b), 23 (76.7%) were
also reported by Nograles et al., (2008), with a significant
correlation between FCHs reported by both studies (r¼ 0.6;
P¼0.0027). However, we did not detect several previously
reported IL-17-induced chemokines, including CXCL3, CXCL5,
S100A7, and S100A12 (Figure 2b). The expression level of
these genes was highly increased by IL-17, using reverse
transcriptase-PCR (RT-PCR) on the same samples (Figure 2c).
Hence, different ‘‘whole genome’’ arrays show variable
sensitivity in detection of IL-17-induced gene products.
TNF-a broadly modulates KC gene expression
TNF-a effects on KCs were also evaluated by Illumina arrays.
We determined a broad genomic response, largely consistent
with previous results using the Affymetrix platform (Banno
et al., 2004). However, FCH induction of inflammatory genes
modulated by 10 and 1ngml1 concentrations of TNF-a was
higher than previous results obtained using a higher TNF-a
stimulus (50ngml1; Banno et al., 2004). We identified 459
genes (502 probes) with altered expression after treatment with
10ngml1 of TNF-a: 333 upregulated genes (371 probes) and
126 downregulated genes (131 probes; Figure 3a and
Supplementary Table S2 online). A smaller number of genes
were regulated by 1ngml1 of TNF-a: 121 upregulated genes
(134 probes) and 45 downregulated genes (45 probes; Figure
3a and Supplementary Table S3 online). A total of 362 probes
(320 genes) were uniquely modulated by 10ngml1 of TNF-a
(250 up- and 112 downregulated) and a small number of 39
probes (37 genes) were induced only by 1ngml1 of TNF-a
(13 up- and 26 downregulated), possibly as high TNF
concentrations inhibit transcription of numerous gene products
(Banno et al., 2004; Figure 3a, Supplementary Table S6
online). Most (90%) probes upregulated by 1ngml1 were also
upregulated by the larger dose (Figure 3a), but the dose–
response relationship as measured by FCH was larger for
10ngml1 (Supplementary Tables S2, S3 online). Despite the
higher number of genes induced by 10ngml1 of TNF-a, key
genes such as MMP9, IL-8, IL1B, and IL1F9 were highly
upregulated by both concentrations, with a larger effect
achieved by the higher concentration (Figure 3b).
Synergistic IL-17/TNF-a interaction to induce gene expression
modifications
Single cytokines were compared with combined IL-17/TNF-a
modulation of KC gene expression. We considered a gene to
be synergistically induced by IL-17 and TNF-a when the
combined effect of the interacting cytokines was greater than
the sum of their separate effects. The synergism could be
positive or negative if the combined effect strongly upregu-
lated or downregulated the gene expression levels (Supple-
mentary Figure S1 online). We also measured effects that
were additive but not synergistic (see Methods for a formal
definition of synergism and additivism). Because of our
particular interest in positive IL-17/TNF-a interactions, we
refer only to positive synergism as synergistic genes. Overall,
the combination of IL-17 with 10 ngml1 of TNF-a synergis-
tically stimulated the expression of 176 probes (160 genes),
compared with 109 probes (99 genes) synergistically stimu-
lated with IL-17 and 1ngml1 of TNF-a, and 78 probes (70
genes) synergistically stimulated by either combination (Figure
3c, Supplementary Table S4 online). Table 1a and b lists
examples of genes that were synergistically or additively
induced by 10ngml1 of TNF-a and IL-17. Key inflammatory
genes previously implicated in the pathogenesis of psoriasis
exist in both lists. An example of the synergistic effect of TNF-a
and IL-17 is induction of IL-19. IL-17 induces IL-19 expression
by 1.79-fold (0.84 log2), whereas TNF slightly reduces
expression. However, the combination of IL-17/TNF-a syner-
gistically induces IL-19 expression by 54.6-fold (5.77 log2).
Similarly, IL-17 and TNF-a individually induce only small
increases in IL-6 expression (1.27- and 1.26-fold, respectively),
but the combination of both cytokines induces IL-6 expression
by 3.89-fold (1.96 log2). As an example of an additive effect,
IL-1F9 could be considered. The expression of IL-1F9 is
induced by IL-17 by 8.75-fold (3.13 log2), and TNF-a by 7.01-
fold (2.81 log2). The combination of these cytokines induces its
expression by 41.4-fold (5.37 log2). Additive IL-17/TNF-a
stimulation is presented in Supplementary Table S5 online.
IL-17 cooperates with TNF-a to significantly enhance
KC-derived cytokines and immunomodulating molecules
To confirm the microarray results of synergistic and additive
genes with IL-17/TNF-a combination, we quantified mRNA
expression of biologically significant genes, including IL-8,
CCL20, LCN2, S100A7, S100A12, and IL-19, in cytokine-
treated KCs by real-time RT-PCR and normalized expression
values to the housekeeping gene hARP (Figure 4a). We
observed a marked synergism in induction of mRNA expres-
sion even for primarily IL-17-regulated genes, such as DEFB4,
S100A7, and CCL20. LCN2 and S100A12, although genes
identified as additive in the microarray experiment, were
synergistically upregulated by RT-PCR, demonstrating a higher
sensitivity of RT-PCR versus the Illumina platform (Figure 4a).
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Kinetics of response
To further investigate IL-17/TNF-a interactions, we harvested
KCs after 6-, 12-, and 24-hour cytokine treatment and
evaluated mRNA gene expression by RT-PCR (Figure 4b).
We observed a rapid response of proinflammatory genes
such as CCL20 and IL-8 at as early as 6 hours of
treatment with IL-17/TNF-a combination. This indicates that
synergistic genes are ‘‘immediate’’ response genes, as
expected for genes regulated by primary transcription factor
circuits.
Interleukin-1, beta
Immediate early response 3
Chemokine (C–C motif) ligand 20
PDZK-1 interacting protein 1
Aldehyde dehydrogenase 1 family, member A3
Chemokine (C–X–C motif) ligand 2
Nucleotide-binding oligomerization domain containing 2
Solute carrier family 11, member 2
Chemokine (C–X–C motif) ligand 1
Spermidine/spermine N1-acetyltransferase 1
Rh family, C glycoprotein
Lipocalin 2
Serpin peptidase inhibitor, clade B, member 4
Interleukin-8
S100 calcium-binding protein A8
S100 calcium-binding protein A9
Small proline-rich protein 2D
NDRG family member 2
Defensin, beta 4
Interleukin-1 family, member 9
Small proline-rich protein 2C
Zinc finger CCCH-type containing 12A
Peptidase inhibitor 3, skin-derived
Co
ntr
ol
IL-
17
200
0
400
600
G
en
e 
ex
pr
es
sio
n/
hA
RP
CXCL3
CXCL5
Co
ntr
ol
IL-
17
100
0
200
300
400
G
en
e 
ex
pr
es
sio
n/
hA
RP
 
S100A12
Co
ntr
ol
IL-
17m
R
N
A 
ex
pr
es
sio
n/
hA
RP
Co
ntr
ol
IL-
17
50
0
100
150
m
R
N
A 
ex
pr
es
sio
n/
hA
RP
S100A7
Illumina Affymetrix*
7 23 14
4 0 5
Up
Down
S100A12
S100A7
CXCL3
CXCL6
DEFB4
LCN2
CXCL1
CXCL2
CCL20
IL-8
IL-1B
IL-1F9
S100A8
S100A9
SPRR2B
SPRR2E
SPRR2C
SPRR2F CXCL5
Illumina
3.46
3.128
2.941
2.505
2.494
2.396
2.082
1.811
1.486
1.448
1.257
1.332
1.189
1.126
1.048
1.028
1.016
0.948
0.877
0.807
0.803
0.617 5.0E–04
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.01
0
0.01
0.14
0
0.11
0.01
0.01
0.19
0.14
0.14
0.01
0
0
0
0
0
0
0
0
0
0 7.898
4.256
4.253
4.783
2.334
0.655
1.104
1.784
2.468
2.585
1.45
4.823
0.789
4.698
0.629
2.587
2.943
0.717 2.0E–04
* Nograles et al. Br J Derm 2008.
4.0E–04
1.0E–04
1.0E–04
2.0E–04
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.01
0
0
0.06
0.04
0
0.03
0
0.01
0
0
0.1
0.01
0
0
0.05
0
0
0
0
0
0
P FDR
2.394
1.116
2.162
2.179
3.913
P FDR Fold change
(log2)
3.0E–04
3.0E–04
3.0E–04
2.0E–04
1.48
Affymetrix*
Symbol Description Fold change
(log2)
DEFB4
IL-1F9
SPRR2C
ZC3H12A
PI3
LCN2
SERPINB4
IL-8
S100A8
S100A9
SPRR2D
NDRG2
RHCG
IL-1B
IER3
CCL20
PDZK1IP1
ALDH1A3
CXCL2
NOD2
SLC11A2
CXCL1
SAT1
50
100
150
200
250
0
Figure 2. Identification of IL-17-regulated genes in human keratinocytes. (a) Comparison of IL-17 signature genes as identified by Illumina and Affymetrix
arrays. (b) A Venn diagram comparing IL-17 response genes on both array platforms. Arrows indicate biologically relevant genes commonly or uniquely
upregulated by each individual platform. (c) Mean values of gene expression normalized to hARP±SD. IL-17 strongly induces mRNA gene expression
in the keratinocytes of a few chemokines that were not detected on the Illumina arrays. FDR, false discovery rate.
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Expression of TNF-a/IL-17 synergistic genes in psoriasis skin
lesions
To investigate the role of IL-17/TNF-a synergism in psoriasis,
we considered two studies that profiled the psoriasis
genotype using the Affymetrix platform (Yao et al., 2008;
Suarez-Farinas et al., 2010). These studies defined the
psoriasis transcriptome as differentially expressed genes
(DEGs) between lesional and non-lesional skin of psoriatic
patients. Among our synergistic genes, 46 were identified as
significantly upregulated in psoriatic skin in the study by Yao
et al. (2008) and 41 by Suarez-Farinas et al. (2010).
Figure 5 identifies multiple synergistic genes that are
ranked among the top 100 upregulated genes in the
transcriptomes described by either Yao et al. (Figure 5a) or
Suarez-Farinas et al. (Figure 5b). Synergistic IL-17/TNF-a
genes in the ‘‘top 100 list’’ include key molecules in the
psoriasis gene signature, including psoriasin (S100A7),
b-defensin (DEFB4), IL-8, CCL20, IL-23 (p19), and CXCL1.
Interestingly, the ‘‘top’’ three psoriasis-related genes in the
study by Yao et al. (S100A7, SerpinB4, and DEFB4) are also
highly ranked IL-17/TNF-a synergistic genes.
To further investigate the relationship between synergistic
genes and the psoriasis gene signature, we used the FCHs
reported in the above-mentioned studies. For synergistic
genes, an impressive correlation was detected between
synergistic effect (defined by synergistic increase) and FCHs
of the psoriasis transcriptome (r¼ 0.785, P¼6.321011 for
Yao et al.; and r¼ 0.62, P¼ 7.6106 for Suarez-Farinas
et al.; Figure 5d and e).
This correlation was reconfirmed with a gene set enrich-
ment analysis evaluating the enrichment of several psoriatic
transcriptomes (Yao et al., 2008; Gudjonsson et al., 2009;
Suarez-Farinas et al., 2010) with respect to IL-17/TNF-a
synergistic effect (Figure 5c). The normalized enrichment
score for all studies was positive (41.75, false discovery rate
o0.0001). This indicates that IL-17/TNF-a synergism induces
a strong induction of most characteristic differentially
expressed genes in psoriasis, advocating for a crucial role
of IL-17/TNF-a combination in the molecular fingerprint of
psoriasis (Suarez-Farinas et al., 2010).
We also sought to determine whether our synergistic gene
profile was correlated with another common inflammatory
skin disease, atopic dermatitis (AD). Unlike the positive
enrichment of upregulated psoriasis genes with the ‘‘syner-
gistic phenotype’’, no such correlation was identified in AD,
as could be appreciated by a negative normalized enrich-
ment score in AD (Figure 5c, Supplementary Figure S2A
online). In comparison with psoriasis (mean FCH¼1.8), the
IL-17/TNF-a synergistic genes showed significantly (P-value
o106) lower FCH induction in AD (mean FCH¼1.2;
Supplementary Figure S2B online), with a distribution of
most synergistic genes (84/108, 77.8%) within the psoriasis
field (Figure 5f). Supplementary Figure S2C online shows that
this higher pathological effect in psoriasis is specific to the
synergistic gene set.
Rapid attenuation of synergistic genes with etanercept
treatment
An absolute proof of synergistic gene regulation of
TNF-a/IL-17 combination in psoriatic skin is difficult.
However, one would expect that synergistic genes would
be more strongly suppressed by TNF inhibition compared
with genes regulated by a single cytokine. To test this
concept, we reexamined expression data from a published
study on the therapeutic mechanism of etanercept, a TNF-a
inhibitor (Zaba et al., 2007, 2009). We compared the mean
reduction in expression of genes regulated solely by TNF-a
versus those by the IL-17/TNF-a synergistic gene set. We
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Figure 3. Tumor necrosis factor (TNF)-a broadly modulates keratinocyte gene expression by Illumina arrays. (a) A Venn diagram comparing the
inflammatory genes modulated by 10 and 1 ng ml1 concentrations of TNF-a. (b) A scatter plot of the effect induced in keratinocytes by 1 ng ml1 versus
10 ng ml1 of TNF-a. Inflammatory genes were highly upregulated by both concentrations, although the higher concentration induced larger fold changes.
(c) IL-17 combination with either TNF-a concentration synergistically stimulated the expression of key psoriasis genes.
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Table 1. Selected genes synergistically or additively induced by TNF-a of 10 ngml1 and IL-17
Fold change (log2)
Symbol Description IL-17 alone TNF-a alone IL-17+TNF-a
(a)
Cytokines and chemokines IL-19 Interleukin-19 0.84 0.12 5.77
IL-8 Interleukin-8 1.39 1.88 4.39
IL-23A Interleukin-23, alpha subunit p19 0.74 0.47 3.27
CCL20 Chemokine (C–C motif) ligand 20 1.05 0.94 3.01
IL-6 Interleukin-6 (interferon, beta 2) 0.35 0.33 1.96
CXCL1 Chemokine (C-X-C motif) ligand 1 0.80 0.20 1.65
TNF Tumor necrosis factor (TNF superfamily, member 2) 0.13 0.95 1.43
IL-17C Interleukin-17C 0.08 0.15 1.35
CXCL5 Chemokine (C–X–C motif) ligand 5 0.23 0.15 1.02
Immune response and
inflammatory genes
DEFB4 Defensin, beta 4 3.46 0.67 6.26
CFB Complement factor B 0.53 1.14 3.35
S100A7A S100 calcium-binding protein A7A 0.15 0.10 3.19
S100A7 S100 calcium-binding protein A7 0.82 0.28 2.72
PLAT Platelet-derived growth factor receptor-like 0.64 0.04 2.67
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 0.06 0.25 0.87
MAP2K3 Mitogen-activated protein kinase kinase 3 0.11 0.05 0.78
PTGE2 Prostaglandin E synthase 2 0.12 0.18 0.62
TFAP2C Transcription factor AP-2 gamma 0.11 0.12 0.57
MAP2K13 Mitogen-activated protein kinase 13 0.08 0.00 0.56
CSF3 Colony-stimulating factor 3 0.10 0.17 0.84
(b)
Cytokines and chemokines IL-1F9 Interleukin-1 family, member 9 3.13 2.81 5.37
CXCL6 Chemokine (C–X–C motif) ligand 6 1.09 0.55 2.57
IL-1B Interleukin-1, beta 1.19 2.28 3.18
IL-1F5 Interleukin-1 family, member 5 0.55 0.69 1.74
TNF-SF18 Tumor necrosis factor (ligand) superfamily, member 18 0.30 0.00 1.01
Immune response and
inflammatory genes
PI3 Peptidase inhibitor 3, skin derived (SKALP) 2.49 1.59 4.17
LCN2 Lipocalin 2 2.40 0.43 3.60
S100A9 S100 calcium-binding protein A9 1.48 1.73 2.60
MAP3K8 Mitogen-activated protein kinase kinase kinase 8 0.80 0.06 1.40
S100P S100 calcium-binding protein P 0.47 0.32 1.19
S100A12 S100 calcium-binding protein A12 0.25 0.13 0.92
S100A8 S100 calcium-binding protein A8 1.49 1.32 1.98
CEBPA CCAAT/enhancer-binding protein (C/EBP), alpha 0.62 0.21 0.98
Key inflammatory genes previously implicated in the pathogenesis of psoriasis exist in both lists. (a) Synergistic gene list. (b) Additive gene list. Fold change
values are in log2 scale to simplify the comparison of single versus combined cytokine effects.
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found that synergistically regulated genes (for both first and
second weeks of etanercept therapy) showed a greater
reduction in expression compared with genes regulated by
TNF-a alone, with a highly significant difference in response at
week 2 (P¼0.0004), and approaching significance at week 1
(P¼ 0.15; Figure 5g).
DISCUSSION
Th17 T cells have been implicated in several autoimmune
diseases in model systems, as well as in human diseases
(Tesmer et al., 2008; Abraham and Cho, 2009; Di Cesare
et al., 2009; Gaffen, 2009; Crome et al., 2010). In humans,
Th-17 T cells synthesize the inflammatory cytokines IL-17A
and IL-17F, which link innate and adaptive immunity
(Stockinger et al., 2007; Khader et al., 2009). For example,
in human epidermal KCs, IL-17 induces synthesis of
antimicrobial peptides (i.e., defensins, lipocalin, and S100
proteins) and also regulates a group of neutrophil-attracting
CXCL chemokines (Nograles et al., 2008; Harper et al., 2009;
Pelletier et al., 2010). These functions are relevant to skin
alterations in psoriasis (Watanabe et al., 2007). The Th17/
IL-23 pathway is highly increased in psoriatic skin lesions
(Lee et al., 2004; Lowes et al., 2008; Di Cesare et al.,
2009) and is central to psoriasis pathogenesis, as genetic
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susceptibility to psoriasis was linked to IL-23p19 and IL-
23p40 gene variants and to the IL-23 receptor (Nair et al.,
2008, 2009; Elder, 2009).
Numerous clinical trials have now established that
antagonism of the p40 subunit, shared between IL-12 and
IL-23, can suppress psoriasis in 70–80% of patients (Krueger
et al., 2007; Menter, 2009). Emerging studies with IL-17
receptor antagonists showed impressive clinical, histological,
and genomic resolution of psoriasis after only 1 week of
treatment (Russell et al., 2010). These data strongly implicate
IL-17 as the most important pathogenic element in psoriasis.
It is thus surprising that IL-17-regulated genes, defined by
exposure of skin KCs to IL-17 as a single cytokine, comprise
only a small fraction (o1%) of overall transcriptional
alterations in this disease (Yao et al., 2008; Suarez-Farinas
et al., 2010). Hence, from the standpoint of genomic
alterations defining the psoriasis transcriptome, it is most
likely that multiple different cytokines and inflammatory
elements collaborate to create an interactive network of more
than 2000 genes with altered expression (Yao et al., 2008;
Suarez-Farinas et al., 2010).
TNF-a cytokine also appears to have a key pathogenic role,
as many TNF-a-regulated genes are overexpressed in the
psoriatic transcriptome (Yao et al., 2008), and TNF-a
antagonists are highly effective therapeutic agents in
60–80% of patients across many clinical trials (Fantuzzi
et al., 2008; Menter, 2009; Mossner and Reich, 2009). In fact,
the TNF responsiveness of psoriasis is somewhat perplexing,
given the strong association of psoriasis with the IL-23/Th17
pathway (Di Cesare et al., 2009) and the general view that
TNF-a is a master cytokine of innate immunity (Mizgerd et al.,
2001; Gottlieb et al., 2005). We have previously shown that
in psoriasis TNF-a is functionally linked to the IL-23/Th17
pathway by its ability to activate myeloid dendritic cells that
synthesize IL-23 and other regulators of T-cell development
(Gottlieb et al., 2005; Zaba et al., 2007, 2009). Thus, TNF-a
may serve as an indirect activator of Th17 responses through
activating effects on myeloid DCs (Zaba et al., 2007, 2009;
Ortega et al., 2009). We have also associated the therapeutic
response of psoriasis patients to the TNF-a inhibitor etanercept
with suppression of the IL-23/Th17 pathway, rather than a
classic ‘‘sepsis cascade’’ pathway of innate immunity that is
stimulated by TNF-a (Zaba et al., 2007, 2009).
The results of this study identify an alternative way of
interaction between TNF-a and Th17 response pathways to
influence skin inflammation. KCs express both TNF-a and IL-
17 receptors (Albanesi et al., 1999; Boniface et al., 2007)
and, on stimulation by both cytokines, produce many
inflammatory products at levels that are additive or synergis-
tic, compared with single-cytokine effects. Thus, a much
larger set of significant disease-signature genes in the
psoriasis transcriptome can be traced to TNF-a/IL-17 syner-
gism. Furthermore, treatment of psoriasis with etanercept
suppresses synergistic TNF-a/IL-17 gene transcripts to a
greater extent than TNF-a ‘‘single-regulated’’ gene products,
as shown here. The in vivo significance of TNF-a/IL-17
synergism could be ideally validated when results of a recent
clinical trial in psoriasis patients with a potent IL-17 receptor
antagonist will become available (Russell et al., 2010). As in
this recent study complete response was achieved in psoriasis
patients both clinically and genomically, it will be of utmost
importance to examine the therapeutic effects against our
synergistic/additive gene set. Although a potential TNF-a/
IL-17 synergism was suggested by few reports (Albanesi et al.,
1999; Homey et al., 2000; Guilloteau et al., 2010), our
extensive genomic approach expands the list of IL-17/TNF-a-
regulated genes from o20 genes to over 350 genes, many of
which are key molecules in psoriasis pathogenesis, with great
relevance for future disease reversal with either IL-17 or TNF
antagonists. We readily acknowledge that our study identi-
fied positive IL-17/TNF-a interactions only in epidermal KCs,
whereas other cell types in skin, as well as some leukocytes,
also coexpress IL-17 and TNF-a receptors (Maitra et al., 2007;
Pelletier et al., 2010). Thus, TNF-a/IL-17 interactions may
penetrate deeper into the psoriasis transcriptome than we
have demonstrated here and IL-17 interactions with other cell
types have been suggested as a basis for rheumatoid arthritis
(for example Moran et al., 2009).
Finally, although IL-17 has emerged as a cytokine that
links autoimmune or inflammatory reactions in several
distinct tissues or organs (Tesmer et al., 2008; Abraham and
Cho, 2009; Di Cesare et al., 2009; Gaffen, 2009; Crome
et al., 2010), we consider that it is not universally pathogenic
in all inflammatory diseases. AD, which shares a number of
features with psoriasis (Guttman-Yassky et al., 2007), has
lower numbers of Th17 T cells and very little IL-17 mRNA
expression or induction of ‘‘classic’’ IL-17 genes in KCs
(Guttman-Yassky et al., 2008). This study extends cross-
disease IL-17 distinctions by showing a much lower expres-
sion of IL-17/TNF-a synergistic genes in the transcriptome of
AD versus psoriasis skin lesions. Hopefully, future work will
help us to define broader roles of IL-17 and interactive TNF-a/
IL-17 responses in other immune-mediated skin diseases, and
the gene sets that are now defined may be used to explore
gene expression signatures of other diseases for these effects.
In summary, to our knowledge, these data provide insight
into synergistic interactions between IL-17 and TNF-a that are
previously unreported. This synergism appears to have a
beneficial effect from a therapeutic perspective, and could
potentially lead to identification of novel therapeutic targets
to intensify disease suppression.
MATERIALS AND METHODS
Primary KC cultures
Primary KCs (n¼ 4) were cultured in Epilife medium (Cascade
Biologics, Portland, OR) and, once 80% confluent, the medium was
supplemented with or without the following cytokines: recombinant
human (rh)-IL-17 (R&D System, Minneapolis, MN) of 200 ngml1
and TNF-a (Sigma-Aldrich, St Louis, MO; 1 ngml1 or 10 ngml1)
for 24 hours before harvesting for other analyses. For the time-course
experiment, cells were collected after 6-, 12-, and 24-hour
treatment. See Supplementary Methods.
Reverse transcriptase-PCR
RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia,
CA) and on-column DNAse digestion (RNAse-free DNAse Set,
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Qiagen), and used for either RT-PCR or gene array. RT-PCR was
performed using EZ PCR core reagents, primers, and probes (Applied
Biosystems, Foster City, CA) as previously published (Chamian et al.,
2005).
Gene array
Total RNA was amplified and labeled using the Message Amp
Premier RNA Amplification Kit (Ambion, Austin, TX) and biotinylted
cRNA was hybridized to Illumina human HT-12 Bead Chip
(Illumina, San Diego, CA). See Supplementary Methods for details.
Statistical analysis
Statistical analysis was performed using R language (www.
R-project.org) and Bioconductor packages (www.bioconductor.org).
A mixed-effects linear model was fitted to log2 expression values and
hypotheses were tested using a moderated t-test and P-values
adjusted by the Benjamini–Hochberg procedure. A gene was
considered to pass the test if the false discovery rate was o0.3
and FCH was 41.3.
To scan for synergistic genes across the 48,802 probes available
in Illumina chips, we needed a formal definition of synergy. We
adapted the theory presented by Verrier et al. (2001) and designed a
series of tests to identify synergistic and additive genes. The formal
definition and detailed statistics are presented in Supplementary
Methods.
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